The following table represents the Company’s available-for-sale investments by major security type as of December 31, 2021 and 2020 (in thousands): December 31, 2021 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Total Fair Value Investments: Commercial paper $ 21,773 $ — $ — $ 21,773 Corporate securities 12,072 2 (7) 12,067 Foreign government securities 1,324 — (2) 1,322 Total available-for-sale investments $ 35,169 $ 2 $ (9) $ 35,162 December 31, 2020 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Total Fair Value Investments: Commercial paper $ 18,179 $ — $ — $ 18,179 Corporate securities 13,597 29 (1) 13,625 U.S. government securities 64,383 7 (4) 64,386 Total available-for-sale investments $ 96,159 $ 36 $ (5) $ 96,190 The Company reviews available-for-sale investments for other-than-temporary impairment loss periodically. The Company considers factors such as the duration, severity of and reason for the decline in value, the potential recovery period and our intent to sell. For debt securities, the Company also consider whether (i) it is more likely than not that the Company will be required to sell the debt securities before recovery of their amortized cost basis and (ii) the amortized cost basis cannot be recovered as a result of credit losses. During the years ended December 31, 2021 and 2020, the Company did not recognize any other-than-temporary impairment losses. All marketable securities with unrealized losses have been in a loss position for less than twelve months. Note 5. Inventory The components of inventories consisted of the following (in thousands): Raw materials $ 5,181 $ 2,874 Work in process 7,442 4,247 Finished goods 5,495 1,232 Inventory $ 18,118 $ 8,353 December 31, 2021 December 31, 2020 Inventory reserves were $1.0 million and $2.2 million at December 31, 2021 and December 31, 2020, respectively. XERIS BIOPHARMA HOLDINGS, INC. Notes to Consolidated Financial Statements 105
RkJQdWJsaXNoZXIy NTIzOTM0